Review





Similar Products

ddavp  (Ferring Pharmaceuticals)
86
Ferring Pharmaceuticals ddavp
Ddavp, supplied by Ferring Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/desmopressin/ddavp/pmc12830292-22-14-11
Average 86 stars, based on 1 article reviews
ddavp - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
desmopressin acetate hydrate  (Ferring Pharmaceuticals)
86
Ferring Pharmaceuticals desmopressin acetate hydrate
Desmopressin Acetate Hydrate, supplied by Ferring Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/desmopressin/desmopressin/pmc12830292-22-0-11
Average 86 stars, based on 1 article reviews
desmopressin acetate hydrate - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
desmopressin acetate ddavp  (Ferring Pharmaceuticals)
86
Ferring Pharmaceuticals desmopressin acetate ddavp
Desmopressin Acetate Ddavp, supplied by Ferring Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/desmopressin/desmopressin/pmc12830292-705-3-8
Average 86 stars, based on 1 article reviews
desmopressin acetate ddavp - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
desmopressin odt  (Ferring Pharmaceuticals)
86
Ferring Pharmaceuticals desmopressin odt
Flowchart of patients included in the survey. The safety analysis set comprised 1049 patients who had received <t>desmopressin</t> and for whom case report forms were collected by the end of March 2022.
Desmopressin Odt, supplied by Ferring Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/desmopressin/desmopressin/pmc12995508-160-15-0
Average 86 stars, based on 1 article reviews
desmopressin odt - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
desmopressin  (Ferring Pharmaceuticals)
86
Ferring Pharmaceuticals desmopressin
Flowchart of patients included in the survey. The safety analysis set comprised 1049 patients who had received <t>desmopressin</t> and for whom case report forms were collected by the end of March 2022.
Desmopressin, supplied by Ferring Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/desmopressin/desmopressin/pmc12995508-157-0-10
Average 86 stars, based on 1 article reviews
desmopressin - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier
nephrology desmopressin  (Wolters Kluwer Health)
86
Wolters Kluwer Health nephrology desmopressin
Flowchart of patients included in the survey. The safety analysis set comprised 1049 patients who had received <t>desmopressin</t> and for whom case report forms were collected by the end of March 2022.
Nephrology Desmopressin, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/desmopressin/desmopressin+nephrology/10__34067_slash_kid__0000001185-112-13-2
Average 86 stars, based on 1 article reviews
nephrology desmopressin - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


Flowchart of patients included in the survey. The safety analysis set comprised 1049 patients who had received desmopressin and for whom case report forms were collected by the end of March 2022.

Journal: Lower Urinary Tract Symptoms

Article Title: Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan

doi: 10.1111/luts.70052

Figure Lengend Snippet: Flowchart of patients included in the survey. The safety analysis set comprised 1049 patients who had received desmopressin and for whom case report forms were collected by the end of March 2022.

Article Snippet: Ferring Japan has previously reported interim PMS results on the safety of long‐term use of desmopressin ODT in 300 patients included in the safety analysis set, followed for up to 12 weeks post‐treatment [ ].

Techniques:

Desmopressin continuation status and reasons for discontinuation during the first 12 weeks of treatment (A, B) and during weeks 12–52 weeks (C, D).

Journal: Lower Urinary Tract Symptoms

Article Title: Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan

doi: 10.1111/luts.70052

Figure Lengend Snippet: Desmopressin continuation status and reasons for discontinuation during the first 12 weeks of treatment (A, B) and during weeks 12–52 weeks (C, D).

Article Snippet: Ferring Japan has previously reported interim PMS results on the safety of long‐term use of desmopressin ODT in 300 patients included in the safety analysis set, followed for up to 12 weeks post‐treatment [ ].

Techniques:

Response to hyponatremia and subsequent patient outcomes. (A) Response following the onset of hyponatremia after administration of desmopressin for up to 12 weeks. (B) Time to recover of hyponatremia in patients who developed hyponatremia from desmopressin administration to 12 weeks. (C) Outcomes of hyponatremia event. (D) Frequency of patient outcomes by interventions for desmopressin. (E) Time from discontinuation or termination of desmopressin administration to recovery or resolution of symptoms.

Journal: Lower Urinary Tract Symptoms

Article Title: Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan

doi: 10.1111/luts.70052

Figure Lengend Snippet: Response to hyponatremia and subsequent patient outcomes. (A) Response following the onset of hyponatremia after administration of desmopressin for up to 12 weeks. (B) Time to recover of hyponatremia in patients who developed hyponatremia from desmopressin administration to 12 weeks. (C) Outcomes of hyponatremia event. (D) Frequency of patient outcomes by interventions for desmopressin. (E) Time from discontinuation or termination of desmopressin administration to recovery or resolution of symptoms.

Article Snippet: Ferring Japan has previously reported interim PMS results on the safety of long‐term use of desmopressin ODT in 300 patients included in the safety analysis set, followed for up to 12 weeks post‐treatment [ ].

Techniques:

Flowchart of patients included in the survey. The safety analysis set comprised 1049 patients who had received desmopressin and for whom case report forms were collected by the end of March 2022.

Journal: Lower Urinary Tract Symptoms

Article Title: Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan

doi: 10.1111/luts.70052

Figure Lengend Snippet: Flowchart of patients included in the survey. The safety analysis set comprised 1049 patients who had received desmopressin and for whom case report forms were collected by the end of March 2022.

Article Snippet: Desmopressin orally disintegrating tablets (ODT, 25 and 50 μg; MINIRINMELT; Ferring Pharmaceuticals, Parsippany, NJ) were approved in Japan in June 2019 and launched in September 2019 for the treatment of nocturia due to NP in men.

Techniques:

Desmopressin continuation status and reasons for discontinuation during the first 12 weeks of treatment (A, B) and during weeks 12–52 weeks (C, D).

Journal: Lower Urinary Tract Symptoms

Article Title: Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan

doi: 10.1111/luts.70052

Figure Lengend Snippet: Desmopressin continuation status and reasons for discontinuation during the first 12 weeks of treatment (A, B) and during weeks 12–52 weeks (C, D).

Article Snippet: Desmopressin orally disintegrating tablets (ODT, 25 and 50 μg; MINIRINMELT; Ferring Pharmaceuticals, Parsippany, NJ) were approved in Japan in June 2019 and launched in September 2019 for the treatment of nocturia due to NP in men.

Techniques:

Response to hyponatremia and subsequent patient outcomes. (A) Response following the onset of hyponatremia after administration of desmopressin for up to 12 weeks. (B) Time to recover of hyponatremia in patients who developed hyponatremia from desmopressin administration to 12 weeks. (C) Outcomes of hyponatremia event. (D) Frequency of patient outcomes by interventions for desmopressin. (E) Time from discontinuation or termination of desmopressin administration to recovery or resolution of symptoms.

Journal: Lower Urinary Tract Symptoms

Article Title: Long‐Term Safety of Desmopressin Orally Disintegrating Tablets in Men With Nocturia due to Nocturnal Polyuria: Final Results of a Specified Drug Use‐Results Survey in Japan

doi: 10.1111/luts.70052

Figure Lengend Snippet: Response to hyponatremia and subsequent patient outcomes. (A) Response following the onset of hyponatremia after administration of desmopressin for up to 12 weeks. (B) Time to recover of hyponatremia in patients who developed hyponatremia from desmopressin administration to 12 weeks. (C) Outcomes of hyponatremia event. (D) Frequency of patient outcomes by interventions for desmopressin. (E) Time from discontinuation or termination of desmopressin administration to recovery or resolution of symptoms.

Article Snippet: Desmopressin orally disintegrating tablets (ODT, 25 and 50 μg; MINIRINMELT; Ferring Pharmaceuticals, Parsippany, NJ) were approved in Japan in June 2019 and launched in September 2019 for the treatment of nocturia due to NP in men.

Techniques: